bpc 157 and tesamorelin The Peptide Honeymoon Needs to End., BPC-157: big “healing” claims, no solid human tissue-repair data., Tesamorelin: a real drug, but for HIV-associated lipodystrophy, not “belly fat” for everyone., tesamorelin and bpc 157 stack

Common contributing factors include poor posture, sedentary lifestyle, improper lifting technique, excess body weight, and genetic predisposition

Compounded versions range $300 to $600 monthly where available

What is missing There is no published human pharmacokinetic study of subcutaneous AOD-9604, no published human topical or intranasal exposure data, no Phase 3 efficacy trial, no long-term safety data beyond 24 weeks, and no published human cartilage or joint outcome data

Associate Professor of Medicine, Mayo Clinic College of Medicine and Science Moira Hilscher, MD Fellow in Gastroenterology and Hepatology, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Rochester, Minnesota